 This study evaluates the combination of CBT-1 and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mgm2 or less of doxorubicin. Participants will receive CBT-1 on days 1-7 of each 21-day cycle, as well as doxorubicin on days 5 and 6. 